Nomenclature
CAS number: 110703-94-1
3,4-Dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic
acid; 2-[4-oxo-3-[5-(trifluoromethyl)benzothiazol-2-ylmethyl]-3,4-dihydrophthalazin-1-yl]acetic
acid; CP-73850.
C
19H
12F
3N
3O
3S; mol wt 419.38.
C 54.41%, H 2.88%, F 13.59%, N 10.02%, O 11.45%, S 7.65%.
Description and references
Aldose reductase inhibitor. Prepn: B. L.
Mylari et al., EP 222576; E. R. Larson, B. L. Mylari, US 4939140 (1987, 1990 both to Pfizer); B. L. Mylari et al. J. Med. Chem. 34, 108 (1991).
Pharmacology: B. Tesfamariam et al., J. Cardiovasc. Pharmacol. 21, 205 (1993);
B. Tesfamariam et al., Am. J. Physiol. 265, H1189 (1993). Clinical pharmacokinetics: P. B.
Inskeep et al., J. Clin. Pharmacol. 34, 760 (1994).
Properties
Crystals, mp 197-198°. pKa (dioxane/water): 5.46 (1:1); 6.38 (2:1). Log P (n-octanol/water): 3.43.Therapeutic Category
Treatment of diabetic complications.
Keywords
Aldose Reductase Inhibitor